EDGAR Filing Documents for 0000950103-17-002656

Form 8-K - Current report:

SEC Accession No. 0000950103-17-002656

Filing Date

2017-03-21

Accepted

2017-03-21 16:49:44

Documents

Period of Report

2017-03-20

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	dp74230_8k.htm	8-K	38224
2	EXHIBIT 4.1	dp74230_ex401.htm	EX-4.1	1395898
3	EXHIBIT 10.1	dp74230_ex1001.htm	EX-10.1	1611348
4	EXHIBIT 99.1	dp74230_ex9901.htm	EX-99.1	17077
5	GRAPHIC	image_001.jpg	GRAPHIC	9867
6	GRAPHIC	image_002.jpg	GRAPHIC	9867
	Complete submission text file	0000950103-17-002656.txt		3091515

Mailing Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8

Business Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8 514-744-6792

Valeant Pharmaceuticals International, Inc. (Filer) CIK: 0000885590 (see all company filings)